ライフサイエンスコーパス: prophylaxis

1 s, such as antiretrovirals, for pre-exposure prophylaxis.

2 ty-five patients received 197 courses of ISA prophylaxis.

3 of bIFI, notably IPA, using ISA for primary prophylaxis.

4 seline and after 30, 60, 90, and 180 days of prophylaxis.

5 with men who were not using oral preexposure prophylaxis.

6 significantly with vs without ciprofloxacin prophylaxis.

7 tiation and might not be preventable through prophylaxis.

8 s, after a median duration of 14 days of ISA prophylaxis.

9 ed donor HCT (2005-2013) with T/S-based GvHD prophylaxis.

10 tudy to determine the role of ISA as primary prophylaxis.

11 114 eligible randomized trials of antibiotic prophylaxis.

12 n of viral shedding or effective preexposure prophylaxis.

13 ible individuals or for use as post-exposure prophylaxis.

14 l HIV exposure rates result in cotrimoxazole prophylaxis.

15 usceptible to the peri-procedural antibiotic prophylaxis.

16 infants received appropriate antiretroviral prophylaxis.

17 KT) recipients without cytomegalovirus (CMV) prophylaxis.

18 te a lack of evidence for routine antibiotic prophylaxis.

19 l treatment (n=102) along with standard GVHD prophylaxis.

20 d comprehensive analysis of risk factors and prophylaxis.

21 in the current era of immunosuppression and prophylaxis.

22 s safe and effective in patients without CMV prophylaxis.

23 acks, with 52 (46%) patients receiving hemin prophylaxis.

24 a testing hydroxychloroquine as postexposure prophylaxis.

25 tudy of intravenous brincidofovir for HHV-6B prophylaxis.

26 e in contributing to failure of treatment or prophylaxis.

27 ial of CMV intravenous immunoglobulin (IVIG) prophylaxis.

28 or human immunodeficiency virus postexposure prophylaxis.

29 low doses, to enable effective, inexpensive prophylaxis.

30 port lamivudine as an option for preexposure prophylaxis.

31 s, provided that there is adequate infection prophylaxis.

32 t associated with PET was $8,707 compared to prophylaxis.

33 see high value and low risk in recommending prophylaxis.

34 nistration of rabies vaccine for preexposure prophylaxis.

35 PTCY (n = 32) or PTCY + ATG (n = 26) as GVHD prophylaxis.

36 pletion of systemic antibiotics [OVP]) or no prophylaxis.

37 n able to discontinue CGD-related antibiotic prophylaxis.

38 ng-term effectiveness and adverse effects of prophylaxis.

39 ontact, whereas hydroxychloroquine failed as prophylaxis.

40 ccine, a combined approach might improve HIV prophylaxis.

41 th and without the use of topical antibiotic prophylaxis.

42 5% confidence interval {CI}, 1.30-9.08]) and prophylaxis (33.3% vs 4.1%; OR, 11.75 [95% CI, 2.31-59.7

43 ted in 27 patients (35.1%) during antibiotic prophylaxis; 33 patients (42.9%) developed secondary inf

44 lower with preemptive therapy than antiviral prophylaxis (9% [9/100] vs 19% [20/105]; difference, 10%

45 mporary immunosuppression and valganciclovir prophylaxis, a significant effect of CMV infection on th

46 study of high-risk KT recipients without CMV prophylaxis, a single ATG dose decreased the risk of CMV

47 We present a CPG for systemic antibacterial prophylaxis administration in pediatric cancer and HSCT

48 l practice guideline for systemic antifungal prophylaxis administration in pediatric patients with ca

49 e guideline (CPG) for systemic antibacterial prophylaxis administration in pediatric patients with ca

50 eekly oral brincidofovir for cytomegalovirus prophylaxis after allogeneic HCT to study the effect of

51 l (MMF) for graft-versus-host disease (GVHD) prophylaxis after nonmyeloablative conditioning for HLA

52 peptide as a good candidate for pre-exposure prophylaxis against HIV-1.

53 ry immune deficiency diseases (PIDD) and for prophylaxis against infectious diseases.

54 Radiology (ESUR) updated its guidelines for prophylaxis against postcontrast acute kidney injury (PC

55 These antibodies are protective in prophylaxis against seasonal H1N1 viruses in mice.

56 support MK-8591's potential as a preexposure prophylaxis agent.

57 hotrexate or mycophenolate) or standard GVHD prophylaxis alone.

58 ude the use of diuretics, statins, infection prophylaxis and anticoagulation.

59 ults, all CVac subjects received chloroquine prophylaxis and bites from 12-15 P. falciparum-infected

60 Unnecessary prophylaxis and fear of lawsuits amongst private practic

61 ddition, we discuss specific aspects of GVHD prophylaxis and management in the setting of haploidenti

62 compared using risk-reliability adjusted VTE prophylaxis and postoperative VTE event rates.

63 The 2 main strategies for CMV prevention are prophylaxis and preemptive therapy.

64 2 and 3, respectively, had discontinued LET prophylaxis and received preemptive therapy with gancicl

65 the CC embolism syndrome as a basis for both prophylaxis and targeted therapy.

66 matic review included 35 publications on VTE prophylaxis and treatment and 18 publications on VTE ris

67 ts are well tolerated and efficacious in the prophylaxis and treatment of aspergillosis, mucormycosis

68 C1-INH was effective for long-term prophylaxis and treatment of breakthrough attacks with f

69 preventive actions, and recommendations for prophylaxis and treatment of patients with COVID-19 infe

70 Prophylaxis and treatment strategies have been implement

71 ter resuscitation, postresuscitation seizure prophylaxis and treatment, and neuroprognostication.

72 ral vaccines along with subunit vaccines for prophylaxis and treatment.

73 a has been used successfully as postexposure prophylaxis and/or treatment of infectious diseases, inc

74 who experienced CS-CMVi while receiving LET prophylaxis, and 2 other variants (encoding pUL56 E237G

75 k patients received three cycles without CNS prophylaxis, and high-risk patients received six cycles

76 ications, PCI indication, periprocedural AKI prophylaxis, and PCI procedural characteristics, Black r

77 The study suggests a role for nAbs in prophylaxis, and potentially therapy, of COVID-19.

78 rd for data tracking on VTE risk assessment, prophylaxis, and rates.

79 Social distance, prophylaxis, and stopping eye exercises temporary were i

80 n of 75 to 100 once daily for cardiovascular prophylaxis appears to be largely inadequate in reducing

81 ation techniques and technologies and stroke prophylaxis are being explored.

82 CT and careful drug selection for antifungal prophylaxis are of paramount importance.

83 Factors driving vancomycin surgical prophylaxis are poorly understood.

84 Rate control, rhythm control, and stroke prophylaxis are the cornerstones of AF therapy.

85 nisms of BP-lowering medications in migraine prophylaxis are unknown.

86 s support further investigations of free PEG prophylaxis as a potential strategy to ameliorate the AP

87 tic anticoagulation should be considered for prophylaxis, as all coronavirus disease 2019 patients ar

88 studies, the absence of or use of antiviral prophylaxis at <1 year post-transplant was associated wi

89 kidney transplant recipients and a targeted prophylaxis based on simple criteria, such as chronic ly

90 as aimed to investigate if professional oral prophylaxis before scaling and root planing (SRP) has an

91 d fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate).

92 lopment of bNAbs as long-acting pre-exposure prophylaxis candidates for use by men and women.

93 GVHD prophylaxis comprised cyclosporine, mycophenolate mofeti

94 n the antibiotic group (P = 0.72).Antibiotic prophylaxis conferred a 17.7% (95% confidence interval 7

95 Standard antifungal prophylaxis consisted of aerosolized amphotericin B lipi

96 rolled trial compared WOCA prophylaxis to no prophylaxis (control) for 6 months in patients with NB d

97 mocyte globulin 4.5 mg/kg plus standard GVHD prophylaxis (cyclosporine or tacrolimus plus methotrexat

98 e-associated costs due to delayed onset post-prophylaxis disease in the prophylaxis group.

99 Single-dose preoperative antibiotic prophylaxis dramatically reduces post-HALDN infection ra

100 ften prescribed for patients as stress ulcer prophylaxis drugs in the intensive care unit (ICU).

101 Clinical use is primarily limited to prophylaxis due to delayed second-cycle parasite death a

102 analgesia, postoperative nausea and vomiting prophylaxis, early diet advancement, early ambulation, a

103 Prophylaxis effectively prevents CMV infection after sol

104 tients transplanted in the prevalganciclovir prophylaxis era.

105 s, QR-GNB were independently associated with prophylaxis failure (hazard ratio, 3.39; P = .045) and i

106 trial that compared valganciclovir as PET or prophylaxis for 100 days in 205 D+R- liver transplant re

107 Overall, 77 patients received antibiotic prophylaxis for an average of 93 days.

108 Doxycycline prophylaxis for bacterial STIs shows promise.

109 before colorectal surgery and personalizing prophylaxis for carriers is efficacious in reducing SSI.

110 ak recommendation for systemic antibacterial prophylaxis for children receiving intensive chemotherap

111 The standard of care for CNS prophylaxis for children with B-ALL and no overt CNS inv

112 ontrolled trial of PET versus valganciclovir prophylaxis for CMV prevention in D+R- liver transplant

113 trial of hydroxychloroquine as postexposure prophylaxis for COVID-19.

114 virus (CMV) prevention strategy of antiviral prophylaxis for high-risk CMV-seronegative liver transpl

115 of Hematology clinical practice guideline on prophylaxis for hospitalized and nonhospitalized medical

116 and extended taper of antiviral and steroid prophylaxis for MK in high-risk, vascularized herpetic c

117 Prophylaxis for recurrent VTE prevention in subsequent p

118 The usefulness of topical antibiotic prophylaxis for routine oculofacial plastic surgery is n

119 elative costs of preemptive therapy (PET) or prophylaxis for the prevention of CMV disease in high-ri

120 ic Surgeons' guidelines on dental antibiotic prophylaxis for the prevention of endocarditis and prost

121 ized controlled trials examining doxycycline prophylaxis found high efficacy.

122 with 53.3% (42.8-62.8) in the standard GVHD prophylaxis group (adjusted hazard ratio [HR] 0.56, 95%

123 18 (19%) of 97 patients in the standard GVHD prophylaxis group (adjusted odds ratio [OR] 3.49 [95% CI

124 he OVP group compared with 6 (12%) in the no-prophylaxis group (P = .03).

125 p and 41.3% (31.3-51.3) in the standard GVHD prophylaxis group (p=0.032).

126 up and 14.62 (SD 12.26) in the standard GVHD prophylaxis group (p=0.034).

127 ed with 17.5 (9.9-25.1) in the standard GVHD prophylaxis group (p=0.73) and non-relapse mortality was

128 .7) in the anti-thymocyte globulin plus GVHD prophylaxis group compared with 17.5 (9.9-25.1) in the s

129 .6) in the anti-thymocyte globulin plus GVHD prophylaxis group compared with 53.3% (42.8-62.8) in the

130 nts in the anti-thymocyte globulin plus GVHD prophylaxis group were free from immunosuppressive thera

131 ntly for the preemptive therapy vs antiviral prophylaxis group, respectively.

132 oms were more prominent in the standard GVHD prophylaxis group, the mean Center for Epidemiological S

133 n group and in 49 (51%) in the standard GVHD prophylaxis group, the most common being infection and G

134 elayed onset post-prophylaxis disease in the prophylaxis group.

135 use were bug-drug mismatch (27.7%), surgical prophylaxis > 24 hours (17.7%), overly broad empiric the

136 ence following the 2008 change in antibiotic prophylaxis guidelines (relative risk of change 1.06 [95

137 iversal screening and intrapartum antibiotic prophylaxis guidelines but late-onset (LOGBS) rates rema

138 the effect of changes in national antibiotic prophylaxis guidelines on incident infective endocarditi

139 Despite changes in antibiotic prophylaxis guidelines, the crude incidence of infective

140 ore and after changes to national antibiotic prophylaxis guidelines.

141 Surviving animals that received aerophage prophylaxis had fewer methicillin-resistant S. aureus in

142 (T/S)-based graft-versus-host disease (GvHD) prophylaxis has been effective in preventing acute GvHD

143 lly fatal complication of cirrhosis, primary prophylaxis has demonstrated a reduction in decompensati

144 For decades, GVHD prophylaxis has included calcineurin inhibitors, despite

145 ae (ESBL-PE) who receive cephalosporin-based prophylaxis have twice the risk of surgical site infecti

146 occurred in the absence of recent antifungal prophylaxis; however, IC and non-Candida breakthrough IF

147 cacy of weekly oral cyclic antibiotic (WOCA) prophylaxis (ie, the alternate weekly administration of

148 cal trial of preemptive therapy vs antiviral prophylaxis in 205 CMV-seronegative liver transplant rec

149 d antibiotic dosing can achieve pre-exposure prophylaxis in a model of pulmonary melioidosis.

150 Doxycycline is used for primary prophylaxis in a number of infectious diseases.

151 and pharmacodynamics (PKPD) of ciprofloxacin prophylaxis in a pediatric ALL population.

152 e effectiveness of fluoroquinolone-based SBP prophylaxis in an era and area of frequent antibiotic re

153 ondary infections and re-evaluate antibiotic prophylaxis in case of selection of quinolone resistance

154 to attend health-care visits or discontinue prophylaxis in consultation with a health-care provider

155 tential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.

156 disease and lower overall costs compared to prophylaxis in D+R- liver transplant recipients.

157 1.8g n-3 PUFA to standard of care secondary prophylaxis in elderly patients who have survived an AMI

158 ore (R,S)-ketamine- and (2R,6R)-HNK-mediated prophylaxis in female mice.

159 Cotrimoxazole prophylaxis in HEU infants decreased gut microbiome beta

160 Low-dose aspirin is recommended for prophylaxis in high-risk populations.

161 ningful benefits when added to standard GVHD prophylaxis in patients undergoing unrelated donor trans

162 Many are for prophylaxis in patients with prosthetic joint replacemen

163 Ciprofloxacin is used as antimicrobial prophylaxis in pediatric acute lymphoblastic leukemia (A

164 intramuscular dose be given for postexposure prophylaxis in previously unvaccinated persons taking an

165 tiate Pneumocystis jirovecii pneumonia (PJP) prophylaxis in solid organ transplant (SOT) recipients a

166 We assessed MK-8591 as preexposure prophylaxis in the rhesus macaque model of intrarectal c

167 , data supporting the use of ISA for primary prophylaxis in these patients are lacking.

168 iously been directly compared with antiviral prophylaxis in these patients.

169 esistance among subjects who received LET as prophylaxis in this Phase 3 trial was low.

170 nes suggested to continue or reinstitute PJP prophylaxis in those receiving intensified immunosuppres

171 rforming the procedure without antimicrobial prophylaxis increases the incidence of infection.

172 roup efficacy estimates from the preexposure prophylaxis initiative (iPrEx) trial.

173 no data for interventions using pre-exposure prophylaxis, interventions for cisgender men with transg

174 T/S-based GvHD prophylaxis is an effective and acceptable GvHD prophyla

175 Moreover, in cases where prophylaxis is considered necessary, the periods of hydr

176 Systemic antibacterial prophylaxis is one approach that can be used to reduce t

177 Cefazolin-based perioperative antibiotic prophylaxis is the guideline-recommended drug-of-choice

178 ogether with the roles for strict thrombosis prophylaxis, laboratory and imaging studies, and early a

179 The leprosy post-exposure prophylaxis (LPEP) programme was an international, multi

180 Routine chemical venous thromboembolism prophylaxis may be inadequate in preventing venous throm

181 response slowed down tumor progression in a prophylaxis model.

182 study provides initial support that CMV IVIG prophylaxis moderately enhances PC-entry nAB activity in

183 vir, 900 mg, daily for 100 days as antiviral prophylaxis (n = 105).

184 ts will help to define future strategies for prophylaxis of bleeding in AHA.

185 ed influenza vaccine (LAIV) was licensed for prophylaxis of children 2-17 years old in Europe in 2012

186 rminase inhibitor, was recently approved for prophylaxis of CMV infection in adult CMV-seropositive r

187 ne potential interventions for treatment and prophylaxis of coronavirus disease 2019 (COVID-19).

188 of plasma kallikrein in development for the prophylaxis of hereditary angioedema (HAE) attacks.

189 -molecule therapeutics for the treatment and prophylaxis of norovirus infections underscores the need

190 strategic diagnostic approach and antifungal prophylaxis of patients with risk factors will likely en

191 TMP-SMZ may be used safely for prophylaxis of recurrent toxoplasmic retinochoroiditis a

192 that IgG1 ab1 has potential for therapy and prophylaxis of SARS-CoV-2 infections.

193 and an indication for fluoroquinolone-based prophylaxis of SBP.

194 dies are needed to determine whether primary prophylaxis of VTE in patients with PDAC will improve mo

195 nts received six cycles with intrathecal CNS prophylaxis or extended intrathecal treatment if leptome

196 allow their inclusion focus on postexposure prophylaxis or outpatient treatment of milder disease, l

197 f developing CS-CMVi and requiring antiviral prophylaxis or therapy and those who are protected.

198 the way to implement antibody cocktails for prophylaxis or therapy, circumventing or limiting the em

199 There is currently no specific prophylaxis or vaccine against Crimean-Congo haemorrhagi

200 inadequate timing of preoperative antibiotic prophylaxis (OR 1.62, P = 0.047), and application of epi

201 ion on how to treat and provide postexposure prophylaxis (PEP) for plague during pregnancy.

202 munoglobulin (IgG)-based rabies postexposure prophylaxis (PEP) is expensive, restricting access to li

203 disease can be prevented with post-exposure prophylaxis (PEP), which includes the administration of

204 and the impact of doxycycline post-exposure prophylaxis (PEP).

205 In the era of prophylaxis, Pneumocystis pneumonia has become a late-on

206 It is unclear how a targeted prophylaxis/ preemptive antifungal therapy strategy impa

207 A targeted prophylaxis/preemptive therapy strategy within the first

208 n association between uptake of pre-exposure prophylaxis (PrEP) and decreases in HIV diagnoses.

209 d the cost-effectiveness of both preexposure prophylaxis (PrEP) and HIV testing strategies for MSM an

210 cal prevention methods, such as pre-exposure prophylaxis (PrEP) and treatment as prevention (TasP).

211 n, WHO recommends offering oral pre-exposure prophylaxis (PrEP) based on tenofovir to HIV-negative pr

212 Human immunodeficiency virus pre-exposure prophylaxis (PrEP) clinical guidelines recommend men who

213 an immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) decreases HIV transmission.

214 Optimal strategies for pre-exposure prophylaxis (PrEP) engagement in generalised HIV epidemi

215 DF/FTC) co-formulate for use in pre-exposure prophylaxis (PrEP) for the prevention of human immunodef

216 an national HIV plan recommends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prev

217 man immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) has great potential to reduce HIV inc

218 Use of HIV preexposure prophylaxis (PrEP) has increased nationwide, but the mag

219 ed a novel programme to provide pre-exposure prophylaxis (PrEP) in maternal and child health clinics

220 te-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States.

221 Pre-exposure prophylaxis (PrEP) is an effective strategy that reduces

222 gh large-scale provision of HIV pre-exposure prophylaxis (PrEP) is gaining momentum, no systematic me

223 to human immunodeficiency virus preexposure prophylaxis (PrEP) is lack or perceived lack of health i

224 als of candidate agents for HIV pre-exposure prophylaxis (PrEP) might randomly assign participants to

225 trends in prescriptions for HIV preexposure prophylaxis (PrEP) overall and by specialty between 2012

226 man immunodeficiency virus (HIV) preexposure prophylaxis (PrEP) regimens among high-risk populations,

227 isoproxil fumarate/emtricitabine preexposure prophylaxis (PrEP) showed BMD recovery 48 weeks followin

228 When used appropriately, pre-exposure prophylaxis (PrEP) substantially reduces the risk of HIV

229 iral therapy (ART) to treat and pre-exposure prophylaxis (PrEP) to prevent HIV infection are effectiv

230 RPV LA) to improve adherence for preexposure prophylaxis (PrEP) to prevent HIV-1 transmission.

231 population-level impact of HIV pre-exposure prophylaxis (PrEP) use among cisgender male sex workers

232 compared observed concordance in preexposure prophylaxis (PrEP) use with the counterfactual if zero i

233 havior (previous 3 months), HIV pre-exposure prophylaxis (PrEP) use, and Grindr usage.

234 Although effective, some oral pre-exposure prophylaxis (PrEP) users face barriers to adherence usin

235 ting the efficacy and safety of pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alaf

236 HIV preexposure prophylaxis (PrEP) with oral tenofovir/emtricitabine is

237 HIV-uninfected men receiving HIV preexposure prophylaxis (PrEP), we performed KSHV typing with K1 ope

238 ave sex with men (MSM) using HIV preexposure prophylaxis (PrEP).

239 fication, promoting condoms, and preexposure prophylaxis (PrEP).

240 monitor cumulative adherence to pre-exposure prophylaxis (PrEP).

241 In a pre-exposure prophylaxis program for Kenyan women, we detected tenofo

242 In conclusion, brincidofovir prophylaxis reduced HHV-6B reactivation after allogeneic

243 ous thrombosis among different pharmacologic prophylaxis regimens, although our analysis is limited b

244 16) and aerosolized amphotericin B (n = 24) prophylaxis, respectively.

245 preemptive therapy, compared with antiviral prophylaxis, resulted in a lower incidence of CMV diseas

246 embryo cell vaccine, given on a postexposure prophylaxis schedule.

247 Extended duration VTE prophylaxis should be considered in all patients undergo

248 PJP prophylaxis should be considered in SOT recipients with

249 eat hyperhidrosis, facial wrinkles, migraine prophylaxis, spasticity, and spasms, had a significantly

250 isease, graft, and graft-versus-host-disease prophylaxis), ST2 remained associated with NRM only in r

251 dergoing major cancer surgery should receive prophylaxis starting before surgery and continuing for a

252 Two stress ulcer prophylaxis strategies were compared (preferential use w

253 for the development of effective control and prophylaxis strategies.

254 ant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons wit

255 itope mapping of these mAbs and small animal prophylaxis studies revealed a complex landscape with pr

256 interval [CI], 52.3 to 81.2) with nirsevimab prophylaxis than with placebo (2.6% [25 infants] vs. 9.5

257 over a period of 2 years without antibiotic prophylaxis the rate of endophthalmitis was 0.0019% whic

258 l, adequate preoperative systemic antibiotic prophylaxis, the administration of 1 g of vancomycin pow

259 Following letermovir prophylaxis, the HR for all-cause mortality was 0.58 (95

260 t whether the patient has received antiviral prophylaxis, the patient's individual risk profile for C

261 While antiviral agents provide effective prophylaxis, there are several important caveats associa

262 sk, and the availability of HIV pre-exposure prophylaxis, there have been attitudinal changes regardi

263 ent efforts on ensuring patients receive VTE prophylaxis throughout their entire hospitalization.

264 nfection requiring indications for prolonged prophylaxis to be defined.

265 were made to administer systemic antifungal prophylaxis to children and adolescents receiving treatm

266 sphamide as graft-versus-host disease (GVHD) prophylaxis to expand donor options and an optimised ART

267 e clinical advancement of CAB LA preexposure prophylaxis to heterosexual men.

268 of treatment strategies, ranging from stroke prophylaxis to monitoring of antiarrhythmic drug (AAD) t

269 , superiority-controlled trial compared WOCA prophylaxis to no prophylaxis (control) for 6 months in

270 to explore the potential benefits of primary prophylaxis to prevent CDI.

271 effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.

272 The efficacy of antibiotic prophylaxis to prevent spontaneous bacterial peritonitis

273 and challenges around the use of doxycycline prophylaxis to prevent syphilis and other STIs.

274 es should explore the benefit of mold-active prophylaxis to this subgroup of KT recipients at highest

275 The initiation of antimicrobial prophylaxis upon the first day of the ICU stay in comato

276 San Francisco, event-driven HIV pre-exposure prophylaxis using a 2-1-1 regimen was a desirable altern

277 reactivation based on prior use of anti-CMV prophylaxis, viral load, the assessment of CMV-specific

278 ring 2015, routine intracameral moxifloxacin prophylaxis was added in a step-wise fashion throughout

279 Intracameral moxifloxacin prophylaxis was associated with a nearly 4-fold lower ra

280 ation of amphotericin as systemic antifungal prophylaxis was made.

281 ing post-transplant cyclophosphamide as GVHD prophylaxis, we successfully expanded alloBMT donor opti

282 st the routine use of systemic antibacterial prophylaxis were made for children undergoing induction

283 oton pump inhibitors, and the use of primary prophylaxis were not significant predictors of HO-CDI.

284 r risks of SBP development during antibiotic prophylaxis were observed for patients with versus witho

285 ceive guideline-directed cephalosporin-based prophylaxis, which may result in an increased SSI rate.

286 47 patients who received cephalosporin-based prophylaxis with 221 who received ertapenem.

287 eline phase, departmental guidelines advised prophylaxis with a cephalosporin plus metronidazole.

288 al had high rates of IFIs, despite receiving prophylaxis with aerosolized amphotericin B lipid comple

289 For individuals at risk for HIV, preexposure prophylaxis with an oral regimen is recommended or, pend

290 andomly assigned to groups that received the prophylaxis with ciprofloxacin (n = 112) or saline solut

291 randomized, noninferiority trial to compare prophylaxis with ciprofloxacin vs placebo in patients wi

292 d whether ESBL-PE screening and personalized prophylaxis with ertapenem reduces SSI risk among carrie

293 Here, we explored the effectiveness of prophylaxis with free PEG or tolerogenic PEGylated lipos

294 o test the hypothesis that postinduction CNS prophylaxis with intrathecal triple therapy (ITT) includ

295 ain for patients with severe kidney disease, prophylaxis with intravenous normal saline is indicated

296 If used, prophylaxis with levofloxacin was recommended during sev

297 fter recovery from IR (DFO post-IR), (3) DFO prophylaxis with treatment through and post-IR (DFO ppx)

298 ical ventilation, a strategy of stress ulcer prophylaxis with use of proton pump inhibitors vs histam

299 In congenital VWD, prophylaxis with VWF/factor VIII concentrates is general

300 enable optimal care and secondary penicillin prophylaxis within available resources.